Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing

Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.

Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.